The UK and US have forged a important commercial pact that will guarantee zero levies on British medicine products entering the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has committed to raise spending on pharmaceuticals through the public health system. This move guarantees that import taxes on these crucial products will remain at nothing for a duration of three years.
This deal comes after earlier statements to hike duties on patented drug imports, with potential rates mentioned reaching 100%.
"This deal with the UK bolsters the global environment for new treatments and establishes much-needed fairness to American-British drug exports," a release said.
Trade Importance
Pharmaceuticals are one of the UK's most significant export categories to the US, which is by far the biggest buyer for major companies like GSK and AstraZeneca.
Export figures show that in the year to the end of last September, the UK sold drugs worth £11.1bn to the US. This amount accounted for a significant portion of total UK exports in that timeframe.
"This deal secures work, increases funding and facilitates the UK to establish itself as a worldwide center for life sciences," a minister stated.
Detailed UK Commitments
The deal entails several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to double overall public funding on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The amount drug companies must pay back to the NHS to stay within budget will be restricted at 15%. In the past, refunds exceeded 20%.
Broader Context
This agreement comes amid a protracted tension between the pharmaceutical industry and the ministers over drug pricing and NHS adoption.
This friction were exacerbated by assertions that American consumers were charged a premium for the equivalent treatments than people in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or cancelled, while major investments have been pledged toward American operations.
One official publicly accepted that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had declined as a proportion of its resources over the past decade.
